Healthcare Dive spoke with Evolent CEO Frank Williams to discuss why the shift to value-based care has been slow and on the difficulties of selling technology to providers. Of the questions asked, the publication touches on downside risk, the high cost of technology, and the challenges faced in the shift to value-based care.
UPMC Enterprises announces $1 billion commitment to life sciences investments
The Translational Sciences team at UPMC Enterprises will be investing $1 billion by 2024 to develop new drugs, diagnostics, and devices.
Meet the Executive: Wendy Zellner, Vice President of Public Relations at UPMC
At UPMC, Zellner helps to oversee UPMC’s roughly 15-person media group (covering UPMC and Pitt Schools of the Health Sciences), and personally works with UPMC’s Enterprises, International, Information Services, and Quality divisions to identify and tell the organizations’ best stories to the media.